Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period. Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON study in CSU by adding a 360mg single-dose cohort (n=4), and that enrollment in this cohort has commenced. Jasper continues to plan to report initial data from all doses of the BEACON study up through 240mg in CSU during the week of January 6th, 2025. Data from the newly added 360mg single-dose cohort is expected to be reported in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics management to meet virtually with Jefferies
- Jasper shows ‘good responses’ for briquilimab in CIndU, says Stifel
- Morning Movers: Longboard Pharmaceuticals surges following deal to be acquired
- Jasper Therapeutics repoirts data from its SPOTLIGHT study of briquilimab
- Jasper concerns driven by Celldex data ‘overdone,’ says Stifel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
